ABCELLERA BIOLOGICS INC (ABCL)

AbCellera Presents Data on T-Cell Engagers Against Four Tumor Targets at AACR 2024

AbCellera to Report First Quarter 2024 Financial Results on May 7, 2024

The 7 Best Penny Stocks to Buy in Q2 2024

Discover seven penny stocks to buy primed for significant gains in Q2 2024. Don't miss out on these picks or your portfolio could suffer.

AbCellera to Present at the Bloom Burton Healthcare Conference on April 16, 2024

AbCellera to Collaborate with Biogen to Discover Therapeutic Antibodies for Neurological Conditions

AbCellera Announces Four Presentations on T-Cell Engagers at AACR 2024

3 Highly Rated Biotech Stocks to Buy for 300% Gains

Biotech stocks like those discussed here have the potential to produce 300% returns and benefit from high analyst ratings.

Peter Thiel resigns from AbCellera board for personal reasons (NASDAQ:ABCL)

AbCellera (ABCL) said Peter Thiel plans to resign from its board of directors for personal reasons, effective March 7. Read more here.

AbCellera Announces Resignation of Board Member

AbCellera to Present at Upcoming Investor Conferences in March

Interesting ABCL Put And Call Options For March 15th

AbCellera Biologics (ABCL) Q4 2023 Earnings Call Transcript

ABCL earnings call for the period ending December 31, 2023.

AbCellera Biologics GAAP EPS of -$0.51 misses by $0.04, revenue of $38M misses by $0.13M (NASDAQ:ABCL)

AbCellera Biologics reports disappointing FY 2023 results with missed EPS and revenue targets, but shows growth with new partner-initiated program starts.

AbCellera Reports Full Year 2023 Business Results

AbCellera to Report Full Year 2023 Financial Results on February 20, 2024

4 Magnificent Healthcare Stocks to Buy in 2024 and Beyond

Healthcare stocks have underperformed in 2023, but that is expected to change this year.

3 Growth Stocks That Could Go Parabolic in 2024

These innovation-oriented companies could take flight this year.

AbCellera Biologics (ABCL) Shares Cross Above 200 DMA

Absci stock gains as AI drug discovery rallies (NASDAQ:ABSI)

Absci Corporation (ABSI) reaches new highs as AI-led drug development gains momentum, fueled by deals with industry leaders like Nvidia (NVDA). Read more here.

AbCellera to Present at the 42nd Annual J.P. Morgan Healthcare Conference on January 10, 2024

AI Meets Biotech: 3 Top Stocks Transforming Medical Science

The AI revolution is bringing big gains to biotechnology, including drugs, antibodies, and synthetic biology.

KeyBanc sees opportunity in tech-enabled drug discovery stocks (NASDAQ:ABCL)

KeyBanc has initiated coverage of the tech-enabled drug discovery subsector, citing increasing demand for products that can help lower drug development costs. Read more here.

Bag This Bargain Even Cheaper Than Director Montalbano Did

AbCellera to Present at the Piper Sandler 35th Annual Healthcare Conference on November 30, 2023

Recursion Pharma stock spikes after ARK buys (NASDAQ:RXRX)

ARK Innovation ETF (ARKK) buys Recursion Pharma (RXRX) shares, leading to a surge in its stock price and those of its peers in AI drug discovery. Read more here.

AbCellera Presents New Data on Two T-Cell Engager Programs at SITC 2023

AbCellera Biologics (ABCL) Q3 2023 Earnings Call Transcript

ABCL earnings call for the period ending September 30, 2023.